This post was just published on ZYX Short Change Alert.
RNA is a development stage biotech company. Until yesterday shares had moved up in sympathy with the success at PTCT. Today’s shares are moving up strongly again as investors react to company releasing its presentation to be made at Jeffries on June 4 2014. The up-move on the stock is way overdone. There is an opportunity to make about 40% in a short time but there is high risk of a short squeeze. Further, there is a high risk because the company can be bought out at a much higher price. For these reasons, the best way to control risk is to keep quantities small. Consider starting a 20% tranche in the zone of $9.50 to $10.50. The stock is at $9.66 as of this writing. Target zone is $4.50 to $5.50. Mental stop zone is $11.26 to $12.73.
Due to high risk this is suitable only for those who are very aggressive.
